NCT00091429
Completed
Phase 3
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day
ConditionsAngina
DrugsRanolazine
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Angina
- Sponsor
- Gilead Sciences
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain symptomatic despite daily treatment with the maximum labeled dose of amlodipine (10 mg daily), a calcium channel blocker approved for the treatment of chronic angina. Eligible patients will be randomized to receive ranolazine 1000 mg or placebo twice daily, in addition to a daily dose of 10 mg of amlodipine. Participation in the study will last approximately 3 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)Heterozygous Familial HypercholesterolemiaNCT01709500Regeneron Pharmaceuticals249
Unknown
Phase 3
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)COVID-19NCT04852705Shenzhen Kangtai Biological Products Co., LTD28,000
Completed
Phase 3
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic RhinitisSeasonal Allergic RhinitisNCT05311475Sandoz669
Completed
Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseAlzheimer's DiseaseNCT01767311Eisai Inc.856
Withdrawn
Phase 2
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityRelapsing Multiple SclerosisNCT01404117Teva Branded Pharmaceutical Products R&D, Inc.